Text Size
Trial record 2 of 37 for:    safety and efficacy of pasireotide
Previous Study | Return to List | Next Study

Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00171951
First received: September 13, 2005
Last updated: October 18, 2012
Last verified: October 2012
History of Changes
  Purpose

Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. This study will assess the long-term safety and efficacy of pasireotide in patients with Cushing's disease.


Condition Intervention Phase
Cushing Disease
 Drug: Pasireotide
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease

Resource links provided by NLM:

Drug Information available for: Pasireotide
U.S. FDA Resources

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Long term efficacy (UFC) in patients with Cushing's disease [ Time Frame: at the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Long term safety [ Time Frame: at the end of the study ] [ Designated as safety issue: No ]
  • Tolerability [ Time Frame: at the end of the study ] [ Designated as safety issue: No ]
  • Pharmacokinetics [ Time Frame: at the end of the study ] [ Designated as safety issue: No ]
  • Development of biomarker [ Time Frame: at the end of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 26
Study Start Date: August 2004
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have completed the 15 days of Pasireotide treatment in the CSOM230B2208 study and have achieved normalization of 24-hour urinary free cortisol. Patients who did not achieve normalization of 24 -hour urinary free cortisol may be enrolled if in the opinion of the investigator the patient is getting significant clinical benefits from treatment with Pasireotide .
  • The patient did not experience any unacceptable adverse events of tolerability issues during the original 15 day treatment.
  • Female patients of child bearing potential who have not undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation must agree to use barrier contraception throughout the course of the extension study, and for one month after the study has ended

Exclusion Criteria:

  • Patients who have developed poorly controlled diabetes mellitus as indicated by ketoacidosis or HgbA1C > 10 since starting [study CSOM230B2208]
  • Patients with persistent ALT/AST or alkaline phosphatase levels more than 2.5X ULN, serum creatinine > 2.0 X ULN, serum bilirubin > 2 X ULN
  • Patients with abnormal coagulation (PT and PTT elevated by 30% above normal limits), WBC <3.0x1'000'000'000/L; Hgb <12.0g/dL for females, Hgb <13.0g/dL for males; PLT <100x1'000'000'000/L

Other protocol-defined inclusion / exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00171951

Locations
United States, California
Novartis Investigative Site
Los Angeles, California, United States, 90048
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02114
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19104
United States, Wisconsin
Novartis Investigative Site
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticlas Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00171951     History of Changes
Other Study ID Numbers: CSOM230B2208E1
Study First Received: September 13, 2005
Last Updated: October 18, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Cushing's disease
ACTH
Cortisol
ACTH dependent Cushing's disease

Additional relevant MeSH terms:
Cushing Syndrome
Pituitary ACTH Hypersecretion
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases
Hyperpituitarism
 Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 21, 2013